Adaptive Biotechnologies

ADPT

Market cap $2.36B

Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at Morgan Stanley.

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to earnings weakness, guidance cuts, and potential disruption from stablecoins. We initiated a position in HubSpot for its strong SMB positioning, AI-driven growth, and scalable financials, while exiting Expedia due to recession risks.

Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%.